RELN抗体—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Western blot analysis using HEXA mouse mAb against L1210 (1), and HL7702 (2) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of HeLa cells using HEXA mouse mAb (green) and negative control (red).    

  
  

**Background of RELN Antibody**

The RELN antibody targets Reelin, a large extracellular glycoprotein encoded by the *RELN* gene, crucial for brain development and function. Reelin regulates neuronal migration, cortical layer formation, and synaptic plasticity by signaling through receptors like ApoER2 and VLDLR, which activate downstream adaptor proteins (e.g., Dab1). Dysregulation of Reelin is linked to neurodevelopmental disorders (e.g., autism, schizophrenia) and neurodegenerative diseases (e.g., Alzheimer’s).

RELN antibodies are essential tools in neuroscience research, enabling detection of Reelin expression and distribution via techniques like Western blot, immunohistochemistry, and immunofluorescence. These antibodies help elucidate Reelin's role in health and disease, including its altered expression in psychiatric conditions or amyloid plaque-associated pathologies.

Available as monoclonal or polyclonal forms, RELN antibodies vary in specificity and sensitivity. Monoclonal antibodies offer high consistency, while polyclonal versions may detect multiple epitopes. Validation using *RELN* knockout models ensures antibody specificity. Challenges include cross-reactivity with homologous proteins or isoforms and detecting post-translationally modified Reelin.

Research applications span developmental studies, disease mechanisms, and therapeutic exploration, such as Reelin supplementation strategies. Proper validation and species reactivity (human, mouse, rat) are critical for experimental accuracy, making RELN antibodies pivotal in advancing neurobiological and clinical research.